比利时弥漫性内生型脑桥胶质瘤25年回顾性研究
该研究回顾性分析比利时1994至2018年登记的100例≤18岁DIPG患者,发现近5年发病率升至3.1/百万/年,活检率51.7%、化疗使用58.8%但无显著生存获益,各中心治疗差异大且临床试验入组仅12.6%。
要点
- 比利时DIPG近5年发病率升至3.1/百万/年,高于总体1.8。
- 化疗使用率58.8%但无显著生存获益,仅12.6%入组临床试验。
- 各中心活检率和化疗使用差异大,需加强协作与临床试验入组。
核心结论
- 过去25年比利时DIPG新诊断增多,队列结局与文献相当,但中心间治疗异质性大且临床试验入组有限,亟需中心协作和患者入组试验。
研究设计与样本
- 回顾性收集比利时癌症登记处1994至2018年诊断的DIPG患者,纳入≤18岁且在八家比利时儿科肿瘤中心随访者,共100例,87例资料完整。
主要发现
- 近5年发病率为3.1/百万(0-≤18岁)每年,总体发病率为1.8。
- 诊断时活检率51.7%,其中五分之一与研究相关。
- 8例已知突变分析,其中6例为H3 K27M突变。
- 58.8%患者接受化疗,无显著生存获益。
- 12.6%患者入组临床试验,中位OS和PFS分别为10.49和4.87个月,生存随时间改善。
临床怎么用
- 应推动比利时各儿科肿瘤中心间的协作,并鼓励DIPG患者入组临床试验以改善治疗同质性和结局。
局限性
- 为回顾性登记研究,87例资料完整,突变分析仅8例已知,可能存在选择偏倚和信息不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diffuse intrinsic pontine glioma is a rare disease with a high mortality. Our primary aim was to determine the incidence of this disease in Belgium. Secondly, we wanted to compare the treatment approach of Belgian pediatric oncology centres, to investigate possibilities for improvement. METHODS: We retrospectively collected and analysed data on DIPG-patients diagnosed between 1994 and 2018 and recorded in the Belgian Cancer Registry. We included patients ≤ 18 years who were followed in one of the eight Belgian pediatric oncology centres. RESULTS: We included 100 patients. Files were complete in 87 patients. We observed an increase in diagnoses with an incidence of 3.1 per 1,000,000 persons (aged 0-≤ 18) per year over the last 5 years compared to an overall incidence of 1.8. Biopsy was performed at diagnosis in 51.7% of patients. In one fifth this was study-related. Mutation analysis was known in eight patients, of which six showed the H3 K27M-mutation. 58.8% of patients received chemotherapy, without a significant survival benefit. 12.6% of patients were included in a clinical trial. Biopsy rate and the use of chemotherapy differed widely between centres. Mean OS and PFS were 10.49 and 4.87 months respectively. We observed an improved survival over time. CONCLUSIONS: Over the past 25 years, we observed an increase of new DIPG-diagnoses. Outcome in our cohort is comparable with literature findings. We demonstrate an important heterogeneity in treatment approach between different centres and limited inclusion in clinical trials. Therefore, collaboration between centres and inclusion of patients in clinical trials is much needed.
引用
- Ruttens D, Messiaen J, Ferster A, et al. Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience. J Neurooncol. 2021. PMID: 33939103. doi:10.1007/s11060-021-03766-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。